PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »